文献速递呼吸道感染

连花清咳片辅助治疗儿童肺炎支原体肺炎的随机双盲多中心安慰剂对照试验

Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial
RSS 订阅 · PubMed 高证据 · 肺炎 · 2026-06-26

该研究为前瞻性、多中心、随机、双盲、安慰剂对照试验,纳入160例4-14岁轻症肺炎支原体肺炎患儿,按1:1随机接受常规治疗联合连花清咳片或安慰剂治疗7天。主要症状缓解率在连花清咳片组显著高于安慰剂组(85.9% vs. 65.6%),且安全性良好,无严重不良事件报告。

要点

  • 连花清咳片辅助治疗可显著提高轻症肺炎支原体肺炎患儿第7天主要症状缓解率。
  • 连花清咳片组与安慰剂组不良反应均轻微,无严重不良事件。
  • 在抗生素耐药上升背景下,连花清咳片可作为儿童轻症肺炎支原体肺炎的辅助治疗选择。

核心结论

  • 连花清咳片作为轻症儿童肺炎支原体肺炎的辅助治疗安全有效,可显著改善呼吸道症状,并呈现缩短恢复时间的趋势。

研究设计与样本

  • 前瞻性、多中心、随机、双盲、安慰剂对照试验,共纳入160例4-14岁轻症肺炎支原体肺炎患儿,来自13家医院,历时4个月。
  • 患儿按1:1随机接受常规治疗联合连花清咳片或常规治疗联合安慰剂,疗程7天。
  • 疗效分析纳入128例经中心实验室确认肺炎支原体感染的患儿,安全性分析纳入全部160例。

主要发现

  • 连花清咳片组第7天主要症状缓解率为85.9%,安慰剂组为65.6%,差异有统计学意义(p<0.05)。
  • 两组用药依从性均为98.8%(p>0.05),基线特征均衡(所有p>0.05)。
  • 连花清咳片组未报告严重不良事件。

关键数值与推荐

  • 主要结局为第7天主要症状缓解率,连花清咳片组85.9% vs. 安慰剂组65.6%(p<0.05)。

临床怎么用

  • 对于4-14岁轻症肺炎支原体肺炎患儿,可在常规治疗基础上加用连花清咳片作为辅助治疗,以改善呼吸道症状。

局限性

  • 疗效分析仅纳入128例经中心实验室确认肺炎支原体感染的患儿,而非全部160例随机化患儿。
  • 研究仅纳入轻症患儿,结论不适用于重症或住院患儿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clin Respir J. 2026 Jul;20(7):e70204. doi: 10.1111/crj.70204. ABSTRACT BACKGROUND: Mycoplasma pneumoniae (MP) is a major cause of community-acquired pneumonia in children, with increasing macrolide resistance complicating treatment. Traditional Chinese Medicine (TCM) provides unique benefits for pediatric respiratory infections. PURPOSE: To evaluate the safety and efficacy of Lianhua Qingke (LHQK) tablets as adjunctive therapy in children with M. pneumoniae pneumonia (MPP). STUDY DESIGN: This prospective, multicenter, randomized, double-blind, placebo-controlled trial adhered to the Declaration of Helsinki and was registered in the Chinese Clinical Trial Registry (ChiCTR2300078209). METHODS: A total of 160 children aged 4-14 years with mild MPP were randomized 1:1 to receive conventional therapy plus LHQK or conventional therapy plus placebo for 7 days across 13 hospitals over 4 months. Efficacy analysis included 128 participants with centrally confirmed MP infection; safety analysis included all 160. Baseline characteristics were comparable (all p > 0.05), with 98.8% medication compliance in both groups (p > 0.05). The primary outcome was the major symptom resolution rate by Day 7. RESULTS: The LHQK group showed a significantly higher major symptom resolution rate (85.9% vs. 65.6%, p 0.05), with no serious events reported. CONCLUSION: LHQK is a safe and effective adjunctive TCM therapy for mild MPP in children, offering significant benefits in respiratory symptom alleviation and a favorable safety profile, with a trend toward shorter recovery time, providing a valuable treatment option amid rising antibiotic resistance. PMID: 42357817 | PMC: PMC13304230 | DOI: 10.1111/crj.70204

来源:PubMed 高证据 · 肺炎,查看原文。版权归原作者所有。

引用

  1. PubMed 高证据 · 肺炎:Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。